Pfizer Inc. (PFE) Shares Bought by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 4.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 797,759 shares of the biopharmaceutical company’s stock after acquiring an additional 34,991 shares during the quarter. Pfizer makes up about 0.4% of Mutual of America Capital Management LLC’s holdings, making the stock its 26th largest holding. Mutual of America Capital Management LLC’s holdings in Pfizer were worth $28,943,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Naples Global Advisors LLC increased its holdings in shares of Pfizer by 5.4% in the second quarter. Naples Global Advisors LLC now owns 33,695 shares of the biopharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 1,712 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of Pfizer by 25.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 285,325 shares of the biopharmaceutical company’s stock valued at $10,352,000 after purchasing an additional 57,176 shares during the last quarter. Destination Wealth Management increased its holdings in shares of Pfizer by 962,667.3% in the second quarter. Destination Wealth Management now owns 500,639 shares of the biopharmaceutical company’s stock valued at $18,163,000 after purchasing an additional 500,587 shares during the last quarter. Gagnon Securities LLC increased its holdings in shares of Pfizer by 61.1% in the first quarter. Gagnon Securities LLC now owns 14,708 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 5,581 shares during the last quarter. Finally, Pennsylvania Trust Co increased its holdings in shares of Pfizer by 10.9% in the second quarter. Pennsylvania Trust Co now owns 681,255 shares of the biopharmaceutical company’s stock valued at $28,127,000 after purchasing an additional 67,151 shares during the last quarter. 68.96% of the stock is owned by institutional investors and hedge funds.

In other news, major shareholder Pfizer Inc purchased 55,556 shares of the stock in a transaction dated Monday, October 15th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the transaction, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of the firm’s stock in a transaction on Monday, August 13th. The stock was sold at an average price of $41.00, for a total value of $418,774.00. Following the transaction, the insider now owns 72,672 shares of the company’s stock, valued at $2,979,552. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

Several equities research analysts recently commented on PFE shares. JPMorgan Chase & Co. reaffirmed a “$37.66” rating on shares of Pfizer in a report on Wednesday, July 18th. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, July 31st. BMO Capital Markets reaffirmed a “buy” rating and issued a $42.00 price target on shares of Pfizer in a report on Thursday, July 19th. Bank of America increased their price target on Pfizer from $42.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, August 1st. Finally, Morningstar set a $45.00 price target on Pfizer and gave the company a “buy” rating in a report on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $42.67.

Shares of Pfizer stock opened at $44.28 on Friday. The company has a market capitalization of $264.31 billion, a P/E ratio of 14.90, a price-to-earnings-growth ratio of 2.24 and a beta of 0.88. Pfizer Inc. has a fifty-two week low of $33.20 and a fifty-two week high of $45.81. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.03. The company had revenue of $13.30 billion during the quarter, compared to analyst estimates of $13.53 billion. Pfizer had a return on equity of 25.34% and a net margin of 44.63%. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.67 earnings per share. Equities research analysts predict that Pfizer Inc. will post 3 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be given a dividend of $0.34 per share. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a dividend yield of 3.07%. Pfizer’s dividend payout ratio is currently 51.32%.

COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/11/10/pfizer-inc-pfe-shares-bought-by-mutual-of-america-capital-management-llc.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply